Sangui BioTech International Inc.: - Sales of USD 18,560 in first quarter - Reduction of the operating loss
November 15, 2021 at 04:27 am EST
Share
DGAP-News: Sangui BioTech International Inc.
/ Key word(s): Quarter Results
Sangui BioTech International Inc.: - Sales of USD 18,560 in first quarter - Reduction of the operating loss
15.11.2021 / 10:25
The issuer is solely responsible for the content of this announcement.
Sangui BioTech:
- Sales of USD 18,560 in first quarter
- Reduction of the operating loss
Hamburg, November 15, 2021: In the first three months of fiscal year 2022 (to 30/06/2022) Sangui BioTech International Inc. achieved revenues from royalty income of USD 18,560. In the same period of the previous year the comparable revenue amounted to USD 19,880. Due to lower revenues of the wound spray Granulox, the resulting royalty income in the first three month period of the year decreased by 7% compared to the same period of the previous year.
Operating expenses decreased USD 2,187 or 3% to USD 62,103 during the first quarter. As a result of the above factors, the three month operating loss decreased USD 867 to USD 43,543. Due to the higher exchange rate of the US dollar to the EURO compared to the previous year's reporting date and the resulting increased exchange rate gains from the valuation of loans denominated in EURO, the loss of the first quarter increased by USD 48,072 to USD 27,917.
Sangui BioTech International, Inc. ("SGBI") is a holding company the shares of which are being traded on the OTCQB venture stage marketplace for early stage and developing U.S. and international companies (OTCQB: SGBI). Companies are current in their reporting and undergo an annual verification and management certification process. Sangui shares also trade on the OTC markets of Berlin and Hamburg-Hannover stock exchanges (symbol: SBH). Its purpose is to provide financing and access to the capital markets for the enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent subsidiary of Sangui BioTech International, Inc.
For more information please contact:
Sangui Biotech International, Inc.
Thomas Striepe
e-mail: info@sangui.de
Some of the statements contained in this news release discuss future expectations, contain projections of results of operation or financial condition or state other "forward-looking" information. These statements are subject to known and unknown risks, uncertainties, and other factors that could cause the actual results to differ materially from those contemplated by the statements. The forward-looking information is based on various factors and is derived using numerous assumptions. Important factors that may cause actual results to differ from projections include, among many others, the ability of the Company to raise sufficient capital to meet operating requirements. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," and variations of such words and similar expressions are intended to identify such forward-looking statements. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
15.11.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
Sangui Biotech International, Inc. focuses on the development of pharmaceutical, medical and cosmetic products. The Company develops its products through its German subsidiary, SanguiBioTech AG (Sangui GmbH). It is engaged in seeking to market and selling its products through partnerships with industry partners across the world. It focuses on the development of oxygen carriers capable of providing oxygen transport in humans in the event of acute and/or chronic lack of oxygen due to arterial occlusion, anemia or blood loss whether due to surgery, trauma, or other causes. It focuses its development and commercialization efforts on such artificial oxygen carriers by reproducing and synthesizing polymers out of native hemoglobin of defined molecular sizes. It offers external applications of oxygen transporters in the medical and cosmetic fields in the form of sprays for the healing of chronic wounds and of gels and emulsions for the regeneration of the skin.
SANGUI BIOTECH INTERNATIONAL, INC. 